Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"

Wall Street Zen upgraded shares of Silence Therapeutics (NASDAQ:SLN - Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.

SLN has been the topic of several other research reports. BMO Capital Markets dropped their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group decreased their price target on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a research note on Friday, May 9th. Chardan Capital reiterated a "buy" rating and issued a $35.00 price objective on shares of Silence Therapeutics in a research report on Friday. HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday. Finally, Morgan Stanley lowered their price target on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Silence Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $33.83.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock traded up $0.31 during trading hours on Friday, hitting $5.37. 97,104 shares of the company were exchanged, compared to its average volume of 303,802. The business has a 50-day moving average of $4.25 and a 200-day moving average of $4.90. Silence Therapeutics has a 1 year low of $1.97 and a 1 year high of $22.47.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative return on equity of 56.17% and a negative net margin of 260.55%. Equities analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $134,000. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics in the fourth quarter valued at $26,000. Trexquant Investment LP purchased a new stake in shares of Silence Therapeutics in the fourth quarter valued at $438,000. Barclays PLC boosted its stake in shares of Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after acquiring an additional 2,793 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in Silence Therapeutics during the 4th quarter worth about $250,000. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.